This Company's Co-CEOs Just Bought More Shares. Should You?

Yahoo

23-04-2025

Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into the company's prospects. If those with the most knowledge think it's worth loading up on the stock, maybe other investors do the same -- or so the argument goes.
That brings us to Summit Therapeutics (NASDAQ: SMMT), a clinical-stage biotech whose co-chief executive officers recently bought more shares of the company they lead. Should other investors follow suit? Let's find out.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
On April 8, Summit Therapeutics' co-CEOs, Robert Duggan and Maky Zanganeh, each exercised warrants, financial instruments that grant their holders the right (but not the obligation) to acquire a company's shares at a predetermined price before a particular date. Duggan and Zanganeh's warrants wouldn't have expired until December 2029, but they both chose to go ahead and buy almost 4 million shares (each) of the company they lead for $1.58 per share.
Many investors and some analysts welcomed the move, seeing it as a sign that Summit's co-CEOs expect the company's shares to rise. But before deciding to jump on the bandwagon, it's essential to look at things other than the CEOs' moves. Do Summit Therapeutics' prospects -- beyond this recent development -- justify investing in the stock today?
On the one hand, Summit Therapeutics is a clinical-stage biotech company with a market cap of $20 billion -- which is exceedingly rare for a drugmaker without a single product on the market. Plenty of biotechs with several approved candidates don't have market caps that high. However, Summit's leading candidate, ivonescimab, looks incredibly promising. Last year, it bested Merck's Keytruda -- the world's best-selling medicine -- in a phase 3 clinical trial in one of its most lucrative markets: non-small cell lung cancer (NSCLC), specifically in patients with a PD-L1 protein overexpression.
This might have been in a study conducted in China, but it speaks volumes about ivonescimab, which is already approved in that country. Summit is running several late-stage studies for the drug in the U.S., including in NSCLC. It earned the fast-track designation from the U.S. Food and Drug Administration (FDA) for a specific indication in NSCLC. This designation helps speed up the approval process for medicines that target large unmet needs, and for which there are promising signs of efficacy.
Summit won't stop at NSCLC. Based on the number of clinical trials ivonescimab is undergoing in China, the investigational therapy could target many indications across several forms of cancer. It has the makings of a pipeline in a single drug, just like Keytruda. The therapy's potential explains why Summit's market cap is so high, despite the company not generating a single dollar in revenue. In my view, it's worth it.
True, Summit Therapeutics didn't create ivonescimab itself. It was licensed from its original creator, China-based biopharma Akeso. Summit Therapeutics now holds the rights to market ivonescimab in most regions outside of China, including the most lucrative pharmaceutical areas: the U.S. and Europe. But the fact that Summit isn't ivonescimab's original creator takes nothing away from the biotech: Larger drugmakers often resort to licensing agreements to beef up their pipelines, since early-stage research costs and risks are so high.
Summit stumbled upon a drug that could far exceed blockbuster status through a strategy that better-established companies opt for regularly. Some might say it was just a fluke, but in my view, it says much more about the biotech's leadership than the recent exercise of warrants does. Between ivonescimab's potential and the company's leaders, the stock looks attractive for ordinary investors.
Before you buy stock in Summit Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $532,771!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $593,970!*
Now, it's worth noting Stock Advisor's total average return is 781% — a market-crushing outperformance compared to 149% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of April 21, 2025
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy.
This Company's Co-CEOs Just Bought More Shares. Should You? was originally published by The Motley Fool